糖心直播

Healthcare ethics: should younger people be prioritised?

An interview with Matthew Robson

If there was a medicine that could give both a 20-year-old and a 70-year-old ten more years of life, but only one of them could receive it, which of them would you choose? Most people would choose the younger person, but what happens when those numbers change? Dr Matthew Robson of ESE and Smarter Choices for Better Health has been researching this interesting dilemma for over four years, hoping to help shape fairer policy. 

Dr Matthew Robson鈥檚 early research focused on lab experiments studying inequality aversion and sel铿乻hness in controlled settings. Now, as a postdoctoral researcher at ESE, Robson is dedicated to work that directly in铿倁ences policy and aims to create real-world change. He has been researching the topic of Fair Innings for years. 鈥淭he Fair Innings Argument, explored by philosophers like Bognar and Harris, suggests that individuals with lower life expectancy should be prioritised in healthcare decisions because they have not yet had the chance to live a full life.鈥 

鈥淏ut this is still very vague,鈥 Robson continues. 鈥淲hen have you had your fair innings? If medication would extend the life of both the 30- and 80-year-old by 10 years, we would probably prefer giving it to the younger individual. But what if it only extends the younger person鈥檚 life by one year and the older person鈥檚 by ten? At some point, efficiency becomes a factor.鈥 

A key distinction in this debate is between age and life expectancy. While age is strongly correlated with life expectancy, it is not the decisive factor, Robson explains. 鈥淚magine three individuals: Peter, Joyce, and John. Peter and Joyce are 30 years old, whilst John is 50. Peter and John will die later today, but Joyce will live until she is 70. All live in perfect health throughout their lives. The total years of life they experience are 30, 70, and 50, for Peter, Joyce, and John, respectively.鈥
鈥淚n our studies, most participants prioritise John over Joyce,鈥 Robson says. 鈥淎lthough Joyce is younger, John has a lower life expectancy. This suggests that prioritisation is based on life expectancy rather than age itself. Age serves as a predictor of life expectancy, and because younger people often have lower life expectancy due to illness or other circumstances, they tend to be prioritised. However, it is not their age that drives the decision, but rather the expectation that they will not achieve a full lifespan; their fair innings.鈥 

To understand public attitudes towards fairness in healthcare, Robson has been working with Prof. Tom van Ourti, Prof. Owen O'Donnell and Prof. Erik Schokkaert to study how people in the UK would distribute healthcare resources to individuals with different ages and life expectancies. 鈥淭he NHS is funded by taxpayers. Since we live in a democracy, I would say it鈥檚 logical that those taxpayers should have a say in how their money is spent, especially when it comes to something as important as ethics in healthcare.鈥 

鈥淭he participants of the study are placed in the role of policymakers,鈥 Robson explains. 鈥淭hey are given a fixed budget, and have to allocate resources among different individuals. Three elements vary: the age of the person receiving healthcare, their expected lifespan without intervention, and the effectiveness of the treatment.鈥

鈥淏y varying these factors, we can quantify how much weight participants place on fairness, efficiency, and the prioritisation of individuals with lower life expectancy,鈥 Robson explains. Because attitudes towards fairness in healthcare may differ across cultures, the research is primarily focused on the UK. However, Robson and his colleagues plan to make their experimental and analytical code publicly available on Robsons website, allowing researchers in other countries to replicate the study and compare results. 

鈥淩ight now, most health policies in the UK seem to be mostly focused on cost-effectiveness. The National Institute for Health and Care Excellence (NICE) will mostly look at the benefit on the average population, compared to the cost. We would love to see them look at it with a more distributional scale, assigning more weight to treatments benefiting the people who are worst off,鈥 Robson explains. While these ideas are not yet fully implemented, there are signs of progress. 鈥淎nd it looks like they鈥檙e starting to think about it, which is great.鈥 

Compare @count study programme

  • @title

    • Duration: @duration
Compare study programmes